It is actually not up to DM to make that choice on the future of the company. 

First, I would note something that Don told me: "biotech cos are bought, not sold".  In other words, you don't "market" a biotech company...the buyer knows whether they want to buy it or not...and will pay up.

Second, given various corporate scenarios (buyout vs partnership etc.), I think it is more in the hands of Hepalink and Dart etc. to decide if they want to hang around any more.  I would imagine Dart is a seller of the company...too long a road for no returns so far.  Looking at Hepalink's balance sheet, I am guessing that they too are a seller.  Plus, Hepalink already owns the rights to the China market, which is what they really care about. I am assuming a takeout is fine with the other top shareholders.

Third, the question is what is the right corporate future for RVX.  I firmly believe it is inside that of a big pharma company where they don't have to worry constantly about funding.  It was the lack of sufficient funding in Phase 3 that got RVX into the soup we find ourselves in...a Phase 3 study done on the cheap.  Kudos to DM and his team for bringing the company this far.  But now, this drug has been derisked beyond any doubt and needs several new studies to exploit its full potential.  There are too many synergies in Apabetalone to be dealt with through partnerships.  Too complex for such a multi faceted drug.  IMHO, RVX should be bought by BP, once we get the FDA letter.